Top Ranked Equity Analyst Joins Vital Therapies, Inc.
SAN DIEGO, March 19, 2012 /PRNewswire/ -- Vital Therapies, Inc., a development stage biotechnology company focused on allogeneic cellular therapy for acute liver failure, today announced that it has appointed Duane Nash, MD, JD, MBA, as the company's Chief Business Officer and Medical Director. Dr. Nash joins Vital Therapies, Inc., from Wedbush PacGrow Life Sciences where he was Senior Vice President in Equity Research. According to STARMINE® / Thomson Reuters, Dr. Nash is currently ranked first among 66 equity research analysts nationwide who publish in the biotechnology market, based on prior 12 month return on recommendations.
Dr. Nash received a BA in Biology from Williams College, an MD from Dartmouth Medical School, a JD from the University of California at Berkeley, and an MBA from the University of Oxford. He completed his internship in General Surgery at the University of California at San Francisco, where he served as a member of the liver transplant team. Dr. Nash also practiced as an attorney for six years, most recently at the law firm of Davis Polk, where he focused on intellectual property litigation and corporate matters.
"Liver failure poses a staggering unmet need both in the United States and worldwide," said Dr. Nash. "Fortunately, Vital Therapies' ELAD® has shown unique promise, with preliminary data suggesting it may improve survival among patients with acute liver failure. I'm honored to play a role in the company's upcoming pivotal trials where we hope to confirm preliminary findings, and also in ELAD's subsequent commercialization."
"We are delighted Dr. Nash is joining our program to commercialize ELAD in USA, EU and worldwide," said Terry Winters, PhD, Vital Therapies, Inc.'s Chairman and Chief Executive Officer. "His unique mix of skills and experience in the life sciences will be invaluable in helping to transi